Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.